Compare Vanguard S&P 500 ETF (VOO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard S&P 500 ETF trades at $708.42, while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). Which is the better fit depends on your goals.
| VOO | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $710.71 | $529.65 |
52-Week Low | $580.93 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOO (Vanguard S&P 500 ETF) trades at $710.71, up 0.6% with a bullish technical signal from moving averages. The ETF tracks the S&P 500 index, which recently reclaimed record highs amid strong corporate earnings and AI-driven optimism. Technical indicators show overbought conditions with RSI at 94.45 on the 6-day timeframe, while support levels begin at $708. JPMorgan raised its S&P 500 year-end target to 8,000, citing earnings strength and AI investment payoffs.
The outlook remains positive given robust earnings growth and institutional confidence, though near-term consolidation risks exist from overbought technicals and valuation concerns. Key risks include market breadth weakness and potential September volatility. The ETF's low-cost structure and diversification continue to attract long-term investors seeking S&P 500 exposure.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
